Compounds and compositions for treating conditions associated with LPA receptor activity
AssigneeLhotse Bio, Inc.
InventorsWei Huang, Hui Lei, Zhongmiao Xu, Haizhen Zhang, Qiong Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.
Claims15
A method for treating a disease, disorder, or condition selected from fibrosis, transplant rejection, cancer, osteoporosis, an inflammatory disorder, idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, systemic sclerosis, COVID-19, chronic obstructive pulmonary disease (COPD), neuroinflammation, multiple sclerosis, and Hermansky-Pudlak Syndrome, the method comprising administering to a patient in need thereof an effective amount of a compound selected from:
- or a pharmaceutically acceptable salt thereof.
A method for treating pulmonary fibrosis, the method comprising administering to a patient in need thereof an effective amount of a compound selected from:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.